Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rune Smaaland

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
In patients younger than age 55 years with lymph node-negative breast cancer, proliferation by mitotic activity index is prognostically superior to adjuvant!Tone Hoel Lende, Emiel A M Janssen, Einar Gudlaugsson, et al.
Polish Journal of Pathology : Official Journal of the Polish Society of Pathologists|April 30, 2013
Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancerEinar Gudlaugsson, Jan Klos, Ivar Skaland, et al.
Molecular Oncology|January 5, 2016
Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancerKjersti Tjensvoll, Morten Lapin, Tove Buhl, et al.
International Journal of Colorectal Disease|May 17, 2011
Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapySatu Oltedal, Ole Gunnar Aasprong, Jannicke H Møller, et al.
BMC Surgery|August 27, 2017
Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trialKnut Jørgen Labori, Kristoffer Lassen, Dag Hoem, et al.
BMC Cancer|June 6, 2022
Prognostic value of disseminated tumor cells in unresectable pancreatic ductal adenocarcinoma: a prospective observational studyOddmund Nordgård, Morten Lapin, Kjersti Tjensvoll, et al.
Journal of Biological Rhythms|April 19, 2007
Circadian variations in clock gene expression of human bone marrow CD34+ cellsOleg Tsinkalovsky, Rune Smaaland, Benedikte Rosenlund, et al.
Journal of Translational Medicine|November 8, 2018
Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancerMorten Lapin, Satu Oltedal, Kjersti Tjensvoll, et al.
Molecular Medicine (Cambridge, Mass.)|August 28, 2013
Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancersMarianne Berg, Marianne Guriby, Oddmund Nordgård, et al.
Breast Cancer Research and Treatment|July 10, 2012
The prognostic value of MARCKS-like 1 in lymph node-negative breast cancerKristin Jonsdottir, Hui Zhang, Darshni Jhagroe, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
In patients younger than age 55 years with lymph node-negative breast cancer, proliferation by mitotic activity index is prognostically superior to adjuvant!Tone Hoel Lende, Emiel A M Janssen, Einar Gudlaugsson, et al.
Polish Journal of Pathology : Official Journal of the Polish Society of Pathologists|April 30, 2013
Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancerEinar Gudlaugsson, Jan Klos, Ivar Skaland, et al.
Molecular Oncology|January 5, 2016
Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancerKjersti Tjensvoll, Morten Lapin, Tove Buhl, et al.
International Journal of Colorectal Disease|May 17, 2011
Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapySatu Oltedal, Ole Gunnar Aasprong, Jannicke H Møller, et al.
BMC Surgery|August 27, 2017
Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trialKnut Jørgen Labori, Kristoffer Lassen, Dag Hoem, et al.
BMC Cancer|June 6, 2022
Prognostic value of disseminated tumor cells in unresectable pancreatic ductal adenocarcinoma: a prospective observational studyOddmund Nordgård, Morten Lapin, Kjersti Tjensvoll, et al.
Journal of Biological Rhythms|April 19, 2007
Circadian variations in clock gene expression of human bone marrow CD34+ cellsOleg Tsinkalovsky, Rune Smaaland, Benedikte Rosenlund, et al.
Journal of Translational Medicine|November 8, 2018
Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancerMorten Lapin, Satu Oltedal, Kjersti Tjensvoll, et al.
Molecular Medicine (Cambridge, Mass.)|August 28, 2013
Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancersMarianne Berg, Marianne Guriby, Oddmund Nordgård, et al.
Breast Cancer Research and Treatment|July 10, 2012
The prognostic value of MARCKS-like 1 in lymph node-negative breast cancerKristin Jonsdottir, Hui Zhang, Darshni Jhagroe, et al.
Pageof 4